Surgalign intends to report its 2022 fourth quarter and full year results for the period ending December 31, 2022 later this month and a notice will be sent shortly confirming the date and time, along with conference call and webcast information. The Company estimates it will report full year 2022 revenue of approximately $82.0 million and end the year with approximately $16.3 million in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRGA:
- Surgalign Provides Update on Corporate Restructuring Initiatives and Confirms its Prior 2022 Revenue Guidance
- Surgalign to Participate at the 2023 AAOS Annual Meeting OrthoDome in Las Vegas
- Surgalign announces Medical City Frisco to utilize its HOLO Portal Surgical
- Medical City Frisco is the Latest Hospital to Utilize Surgalign’s HOLO Portal Surgical Guidance System
- Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million